European-based biopharma company MGC Pharmaceuticals (ASX:MXC) has announced that its epilepsy drug, CannEpil, will now be fully covered under Ireland’s Primary Care Reimbursement Service as part of the country’s Medicinal Cannabis Access Programme (MCAP).
This major breakthrough means that CannEpil will be free of charge for Irish patients prescribed the treatment under the MCAP.
With this announcement, the drug will be one of the first EU‐GMP pharmaceutical grade cannabis medicine products to be approved for prescription in Ireland under the MCAP, which falls under Ireland’s Heath Service Executive (HSE).
